REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Five-membered Hetero Ring Containing At Least One Nitrogen Ring Atom (e.g., 1,2,3-triazoles, Etc.) > 1,3,4-thiadiazoles (including Hydrogenated) > Nitrogen Bonded Directly To Ring Carbon Of The Thiazole Ring Nitrogen Bonded Directly To Ring Carbon Of The Thiazole RingNitrogen Bonded Directly To Ring Carbon Of The Thiazole Ring patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/18/07 - 20070015804 - Polymorph of a pharmaceutical A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed. ... 01/18/07 - 20070015803 - Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and sc A method of treating an infectious disease caused by a pathogen comprising administering to a subject in need thereof an effective amount of one or more compounds that inhibit the function of a molecular chaperone, wherein said compound is other than tizoxanide or nitazoxanide. ... 01/04/07 - 20070004788 - Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis ... 12/21/06 - 20060287374 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 ... 12/07/06 - 20060276521 - Thiazole derivatives A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes ... 11/23/06 - 20060264485 - Pro-drugs of n-thiazol-2-yl-benzamide derivatives wherein the variables are as defined in the claims. The compounds are pro-drugs of A2A-receptor ligands with improved aqueous solubility, and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated. ... 10/12/06 - 20060229346 - Method for treating vascular hyperpermeable disease The present invention provides a method for treating a vascular hyperpermeable disease (except macular edema), which method comprises administering to a patient in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. The agents are 2-acylamino thiazole compounds. ... 09/07/06 - 20060199851 - Novel compounds that are useful for improving pharmacokinetics or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase. ... 08/31/06 - 20060194854 - New 2-substituted - 1,3-thiazole compounds The present invention relates to new compounds of formula I, Wherein Y is NR4CONR4, NR4CO, or NR4; R1 is nitro or COR5; R2 is hydrogen or NH2; R3 is C1-6alkyl or C0-6akylaryl wherein C0-6alkylaryl may be substituted by A; R4 is hydrogen; R5 is C1-6alkyl; A is independently selected from ... 08/31/06 - 20060194853 - Alkyl benzamides The present invention relates to alkyl derivatives of nitazoxanide and tizoxanide and isomers thereof. More specifically, the present invention is directed to compounds possessing anti-parasitic, antibacterial, antiviral and antifungal activities, and to methods of treatment and/or prevention of parasitic, bacterial, viral and/or fungal diseases in humans and animals using said ... 08/17/06 - 20060183783 - Aryl carbonyl derivatives as therapeutic agents This invention relates to aryl carbonyl derivativeswhich are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. ... 07/20/06 - 20060160869 - Ubiquitin ligase inhibitors This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use ... 07/13/06 - 20060154975 - Modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof where X is S, O or N; Z is —T—COOR1 or —T—COR1; and T, R, R1, Ra, Rb, Rc, Rd, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds. ... 07/13/06 - 20060154974 - N-thiazol-2-yl-benzamide derivatives wherein the variables are as defined in the claims. The compounds are A2A-receptor ligands, such as antagonists, agonists, reverse agonists or partial agonists, and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated. ... 06/29/06 - 20060142358 - Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes. ... 06/22/06 - 20060135576 - Heterocyclic inhibitors of kinases and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth ... 06/22/06 - 20060135575 - 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof pharmaceutically acceptable acid-addition salts thereof, hydrates or solvates of such derivatives or such pharmaceutically acceptable acid addition salts, intermediates thereto, processes for the preparation thereof, and therapeutic application thereof. ... 06/01/06 - 20060116408 - N-substituted benzothiophenesulfonamide derivatives The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, ... 06/01/06 - 20060116407 - Amide derivatives their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. ... 04/27/06 - 20060089396 - Halogenated benzamide derivatives R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds. ... 04/20/06 - 20060084689 - Thiazole-amine compounds for the treatment of neurodegenerative disorders wherein R1, R3, R4, R5, R6 and R7 are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods of treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds ... 04/13/06 - 20060079563 - Cyclic protein tyrosine kinase inhibitors Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders. ... 03/30/06 - 20060069139 - Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, ... 03/30/06 - 20060069138 - Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, ... 03/09/06 - 20060052426 - Acylaminothiazole derivatives, their preparation and their therapeutic use in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. therapeutic application. ... 01/26/06 - 20060020001 - Use of cathepsin k inhibitors for the treatment of glaucoma Compositions containing inhibitors of cathepsin K (CTSK) expression and/or activity are provided. Methods for the treatment of glaucoma using the compositions of the invention are further provided. ... 01/05/06 - 20060004067 - Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R2, R3, R4, and R5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase. ... 10/27/05 - 20050239853 - New compounds and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-hydroxysteroid dehydrogenase type 1 enzyme. ... 10/27/05 - 20050239852 - 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors Novel compounds selected from 2-(3-aminoaryl) amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and ... 10/13/05 - 20050228031 - Tyrosine kinase inhibitors The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like ... 10/06/05 - 20050222226 - Five-membered cyclic compounds wherein X is oxygen or sulfur, R1 is hydrogen, substituted or unsubstituted alkyl, etc., R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y1 is a direct bond, substituted or unsubstituted alkylene, —CO(CH2)n—, etc., the wavy line means (E)-configuration or (Z)-configuration, R3 is substituted or unsubstituted aryl, ... 09/29/05 - 20050215608 - Bis-aryl thiazole derivatives Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3. The subject compositions are particularly useful in the treatment of obesity and ... 08/25/05 - 20050187272 - New derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them The invention relates to new derivatives of 2-(iminomethyl)amino-phenyl which are NO synthase inhibitors and can trap reactive oxygen species. These compounds can notably be used for the treatment of stroke, of neurodegenerative diseases and of ischemic or hemorragic cardiac or cerebral infarctions. These compounds include: N-{4-[({[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}amino)methyl]phenyl}thiophene-2-carboximidamide; N-{3-[({[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}amino)methyl]phenyl}thiophene-2-carboximidamide; N-(4-{[{[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}(methyl)amino]methyl}phenyl)thiophene-2-carboximidamide; N-[3-({[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]amino}methyl)phenyl]thiophene-2-carboximidamide; N-(3-{[(3,5-di-tert-butyl-4-hydroxybenzyl)amino]methyl}phenyl)thiophene-2-carboximidamide; ... 08/18/05 - 20050182110 - Modulators of glucocorticoid receptor, ap-1, and/or nf-kappabeta activity and use thereof its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where R, R′, Ra, Rb, Rc, Rd, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and ... 08/11/05 - 20050176789 - Modulators of atp-binding cassette transporters The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including CF Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. ... 08/11/05 - 20050176788 - Therapeutic agent for food competence disorder in stomach Use of a therapeutic agent of the present invention greatly alleviates symptoms caused by said disorders, such as early satiety and bloating, because it improves relaxation of gastric fundus and impaired gastric accommodation. ... 08/04/05 - 20050171169 - Combination chemotherapy for helminth infections in which the efficacy and range of parasites treated is enhanced by the instant combination compared to the sum of the effects of the subject drugs administered separately. ... 07/14/05 - 20050154031 - 5-ht2b receptor antagonists The present invention concerns compounds of formula (I): wherein R1 is selected from the group consisting of H, and optionally substituted C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, and phenyl-C1-4 alkyl; R2 and R3 are either: (i) independently selected from H, R, R′, SO2R, C(═O)R, (CH2)nNR5R6, where n is from ... 06/23/05 - 20050137240 - Selective npy (y5) antagonists This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically ... 06/23/05 - 20050137239 - Thiazole derivatives Methods are disclosed for improving the appearance of skin by topical administration of thiazole derivatives which inhibit the formation of advanced glycation endproducts, break advanced glycation endproduct-associated crosslinks, and inhibit the function of glucose oxidase. Cosmetic and pharmaceutical compositions comprising the thiazole derivatives are also disclosed. ... 06/02/05 - 20050119321 - 2-substituted-1,3-thiazole compounds The present invention relates to new compounds of formula I, Wherein Y is NR4CONR4, NR4CO, or NR4; R1 is nitro or COR5; R2 is hydrogen or NH2; R3 is C1-6alkyl or C0-6alkylaryl wherein C0-6alkylaryl may be substituted by A; R4 is hydrogen; R5 is C1-6alkyl; A is independently selected from ... 06/02/05 - 20050119320 - 5-phenylthiazole derivatives and use as pi3 kinase inhibitors in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. ... ### FreshPatents.com Support |